Literature DB >> 9881944

Contemporary brachytherapy approaches in non-small-cell lung cancer.

B S Hilaris1, D A Mastoras.   

Abstract

Brachytherapy has the ability to deliver a higher tumor dose compared to external beam irradiation, while sparing normal tissue outside the tumor; it is the most effective means of delivering conformal radiation and can be tailored to clinical circumstances, either at open surgery or in an ambulatory setting, which is currently the preferred method. Intraoperative lung and/or endobronchial brachytherapy in the management of non-small-cell lung cancer offers a good curative potential in patients with accessible localized tumors, well defined and small to moderate in size, that have not metastasized to the lymph nodes and are technically or medically inoperable. Effective palliation can be frequently obtained by endobronchial brachytherapy on an outpatient procedure basis. Brachytherapy administered simultaneously with chemotherapy is better tolerated than a course of external beam irradiation and chemotherapy.

Entities:  

Mesh:

Year:  1998        PMID: 9881944     DOI: 10.1002/(sici)1096-9098(199812)69:4<258::aid-jso11>3.0.co;2-a

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  3 in total

1.  Combination of cryosurgery and Iodine-125 seeds brachytherapy for lung cancer.

Authors:  Lizhi Niu; Liang Zhou; Kecheng Xu; Feng Mu
Journal:  J Thorac Dis       Date:  2012-10       Impact factor: 2.895

2.  The combined treatment of CT-guided percutaneous 125I seed implantation and chemotherapy for non-small-cell lung cancer.

Authors:  Shengchu Zhang; Yihu Zheng; Panpan Yu; Fuxiang Yu; Qiyu Zhang; Yinxiang Lv; Xiaoxi Xie; Yunxiao Gao
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-16       Impact factor: 4.553

3.  Radiofrequency ablation of primary and metastatic lung tumors: preliminary experience with a single center device.

Authors:  D Laganà; G Carrafiello; M Mangini; L Boni; G Dionigi; M C Fusi; L Cinquepalmi; F Rovera; S Cuffari; C Fugazzola
Journal:  Surg Endosc       Date:  2006-07-20       Impact factor: 4.584

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.